{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:02:56Z","timestamp":1789624976991,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Small Animal Practice"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe clinical outcomes, thromboembolic and haemorrhagic complications, and treatment characteristics in dogs with non\u2010associative immune\u2010mediated haemolytic anaemia treated with rivaroxaban at a UK referral hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Retrospective descriptive study of dogs diagnosed with non\u2010associative immune\u2010mediated haemolytic anaemia and prescribed rivaroxaban as part of their management protocol between January 2018 and July 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty\u2010four dogs met inclusion criteria. Median admission haematocrit was 14.1% (range 7.0% to 25.5%). Primary management of immune\u2010mediated haemolytic anaemia was with corticosteroids (34\/34; 100%), which were the sole agent in 8\/34 (24%). Adjunctive therapies included mycophenolate mofetil (26\/34; 70.6%), azathioprine (1\/34; 2.9%) and leflunomide (1\/34; 2.9%). Rivaroxaban was administered at a median total daily dose of 1.2\u2009mg\/kg\/day (range 1.03 to 1.97\u2009mg\/kg\/day); 29\/34 dogs (85.3%) received concurrent clopidogrel. Confirmed or suspected thromboembolic events occurred in 7\/34 dogs (20.6%), all during initial hospitalisation. Gastrointestinal bleeding occurred in 5\/34 dogs (14.7%); all five were receiving concurrent corticosteroids, mycophenolate mofetil and rivaroxaban. Two bleeding events were classified as major adverse events, including one fatal case. Overall, 26 dogs (76.5%) survived to discharge. Remission was confirmed in 19\/26 discharged dogs (73.1%) at a median of 33\u2009days (range 15 to 156). Relapse occurred in 2\/19 dogs (10.5%) post\u2010remission. Of 21 dogs with follow\u2010up available, 20 (95.2%) were alive at last known contact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Significance<\/jats:title>\n                    <jats:p>This represents one of the largest UK\u2010based cohorts of dogs with non\u2010associative immune\u2010mediated haemolytic anaemia treated with rivaroxaban, demonstrating acceptable survival and remission rates with this thromboprophylaxis protocol. The occurrence of clinically significant gastrointestinal bleeding exclusively in dogs receiving concurrent corticosteroids, mycophenolate mofetil and rivaroxaban represents an important safety signal that warrants consideration and further study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jsap.70202","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:19:32Z","timestamp":1789622372000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective evaluation of outcomes in dogs with non\u2010associative immune\u2010mediated haemolytic anaemia treated with rivaroxaban as a sole or adjunctive thromboprophylaxis agent: 34 cases (2018\u20102024)"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0034-8232","authenticated-orcid":false,"given":"S.","family":"Conway","sequence":"first","affiliation":[{"name":"University of Bristol Veterinary School  Langford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8486-6911","authenticated-orcid":false,"given":"L.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"University of Bristol Veterinary School  Langford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-0708","authenticated-orcid":false,"given":"J.","family":"Reeve","sequence":"additional","affiliation":[{"name":"University of Bristol Veterinary School  Langford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/hematology.2020000151","article-title":"Combining antiplatelet and anticoagulant therapy in cardiovascular disease","volume":"2020","author":"Barnes G.D.","year":"2020","journal-title":"Hematology. American Society of Hematology. Education Program"},{"key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/vec.12795","article-title":"Consensus on the rational use of antithrombotics in veterinary critical care (CURATIVE): domain 3\u2014defining antithrombotic protocols","volume":"29","author":"Blais M.\u2010C.","year":"2019","journal-title":"Journal of Veterinary Emergency and Critical Care"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1939-1676.2002.tb02378.x","article-title":"Prognostic factors for mortality and thromboembolism in canine immune\u2010mediated hemolytic anemia: a retrospective study of 72 dogs","volume":"16","author":"Carr A.P.","year":"2002","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tvjl.2017.03.006","article-title":"Anticoagulant activity of oral rivaroxaban in healthy dogs","volume":"223","author":"Conversy B.","year":"2017","journal-title":"The Veterinary Journal"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/vec.12797","article-title":"Consensus on the rational use of antithrombotics in veterinary critical care (CURATIVE): domain 1\u2014defining populations at risk","volume":"29","author":"Laforcade A.","year":"2019","journal-title":"Journal of Veterinary Emergency and Critical Care"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1748-5827.2002.tb00066.x","article-title":"Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs","volume":"43","author":"Dobson J.M.","year":"2002","journal-title":"Journal of Small Animal Practice"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","DOI":"10.1186\/s13620-024-00277-w","article-title":"Clinical presentation, outcome and prognostic factors in dogs with immune\u2010mediated haemolytic anaemia: a retrospective single\u2010centre study of 104 cases in Ireland (2002\u20132020)","volume":"77","author":"Duclos A.A.","year":"2024","journal-title":"Irish Veterinary Journal"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2460\/ajvr.72.10.1325","article-title":"Independent and combined effects of prednisone and acetylsalicylic acid on thromboelastography variables in healthy dogs","volume":"72","author":"Flint S.K.","year":"2011","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1111\/jvim.16209","article-title":"A retrospective study of adverse effects of mycophenolate mofetil administration to dogs with immune\u2010mediated disease","volume":"35","author":"Fukushima K.","year":"2021","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/jvim.15441","article-title":"ACVIM consensus statement on the diagnosis of immune\u2010mediated hemolytic anemia in dogs and cats","volume":"33","author":"Garden O.A.","year":"2019","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jvim.13642","article-title":"Predicting outcome in dogs with primary immune\u2010mediated hemolytic anemia: results of a multicenter case registry","volume":"29","author":"Goggs R.","year":"2015","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tvjl.2011.03.015","article-title":"Serial assessment of the coagulation status of dogs with immune\u2010mediated haemolytic anaemia using thromboelastography","volume":"191","author":"Goggs R.","year":"2012","journal-title":"The Veterinary Journal"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/jvim.16572","article-title":"Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs","volume":"36","author":"Hafner P.M.","year":"2022","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1939-1676.2010.0505.x","article-title":"Treatment of immune\u2010mediated hemolytic anemia with individually adjusted heparin dosing in dogs","volume":"24","author":"Helmond S.E.","year":"2010","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_16_1","first-page":"555","article-title":"Immune\u2010mediated hemolytic anemia in dogs","volume":"38","author":"Jutkowitz L.A.","year":"2008","journal-title":"Veterinary Clinics of North America: Small Animal Practice"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1476-4431.2012.00824.x","article-title":"Prothrombotic mechanisms and anticoagulant therapy in dogs with immune\u2010mediated hemolytic anemia","volume":"23","author":"Kidd L.","year":"2013","journal-title":"Journal of Veterinary Emergency and Critical Care"},{"key":"e_1_2_11_18_1","first-page":"629","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy","volume":"77","author":"Kumbhani D.J.","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1111\/jvim.17216","article-title":"Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs","volume":"38","author":"Lynch A.M.","year":"2024","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2460\/javma.2001.218.1308","article-title":"Correlation between leukocytosis and necropsy findings in dogs with immune\u2010mediated hemolytic anemia: 34 cases (1994\u20131999)","volume":"218","author":"McManus P.M.","year":"2001","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/vec.12480","article-title":"Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune\u2010mediated hemolytic anemia","volume":"26","author":"Morassi A.","year":"2016","journal-title":"Journal of Veterinary Emergency and Critical Care"},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/vec.12286","article-title":"Use of enoxaparin in dogs with primary immune\u2010mediated hemolytic anemia: 21 cases","volume":"25","author":"Panek C.M.","year":"2015","journal-title":"Journal of Veterinary Emergency and Critical Care"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/PAS.0b013e31816bf3fe","article-title":"Mycophenolate mofetil\u2010related gastrointestinal mucosal injury: variable injury patterns including graft\u2010versus\u2010host disease\u2010like changes","volume":"32","author":"Parfitt J.R.","year":"2008","journal-title":"The American Journal of Surgical Pathology"},{"key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel M.R.","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","DOI":"10.1111\/jvim.70014","article-title":"Monitoring of rivaroxaban therapy in hypercoagulable dogs","volume":"39","author":"Phillips E.M.","year":"2025","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/01652176.2011.604979","article-title":"Canine idiopathic immune\u2010mediated haemolytic anaemia: a review with recommendations for future research","volume":"31","author":"Piek C.J.","year":"2011","journal-title":"Veterinary Quarterly"},{"key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1939-1676.2008.0060.x","article-title":"Idiopathic immune\u2010mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs","volume":"22","author":"Piek C.J.","year":"2008","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1748-5827.2010.00935.x","article-title":"Evaluation of platelet activation in canine immune\u2010mediated haemolytic anaemia","volume":"51","author":"Ridyard A.E.","year":"2010","journal-title":"Journal of Small Animal Practice"},{"key":"e_1_2_11_29_1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1939-165X.2011.00364.x","article-title":"Effect of prednisone administration on coagulation variables in healthy beagle dogs","volume":"40","author":"Rose L.J.","year":"2011","journal-title":"Veterinary Clinical Pathology"},{"key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/ddr.21118","article-title":"Coagulation assays in patients with new oral anticoagulants (NOACs): why? when?","volume":"74","author":"Samama M.M.","year":"2013","journal-title":"Drug Development Research"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5326\/15473317-37-3-220","article-title":"Hemostatic abnormalities in dogs with primary immune\u2010mediated hemolytic anemia","volume":"37","author":"Scott\u2010Moncrieff J.C.","year":"2001","journal-title":"Journal of the American Animal Hospital Association"},{"key":"e_1_2_11_32_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/modpathol.2009.44","article-title":"Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil","volume":"22","author":"Selbst M.K.","year":"2009","journal-title":"Modern Pathology"},{"key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/jvim.17004","article-title":"Comparison of timing of relapse in dogs with nonassociative immune\u2010mediated hemolytic anemia, thrombocytopenia, or polyarthritis","volume":"38","author":"Sparrow R.","year":"2024","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvim.12028","article-title":"Systematic review of evidence relating to the treatment of immune\u2010mediated hemolytic anemia in dogs","volume":"27","author":"Swann J.W.","year":"2013","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_35_1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jvim.15463","article-title":"ACVIM consensus statement on the treatment of immune\u2010mediated hemolytic anemia in dogs","volume":"33","author":"Swann J.W.","year":"2019","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/vec.13199","article-title":"Clinical features and posttreatment monitoring of dogs administered rivaroxaban (2018\u20132020): 19 cases","volume":"32","author":"Tracy A.L.","year":"2022","journal-title":"Journal of Veterinary Emergency and Critical Care"},{"key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies","volume":"105","author":"Turpie A.G.G.","year":"2011","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_11_38_1","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1292\/jvms.19-0605","article-title":"Treatment with rivaroxaban and monitoring of the coagulation profiles in two dogs with venous thromboembolism","volume":"82","author":"Uchida M.","year":"2020","journal-title":"Journal of Veterinary Medical Science"},{"key":"e_1_2_11_39_1","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2460\/javma.2005.226.1869","article-title":"Evaluation of prognostic factors, survival rates, and treatment protocols for immune\u2010mediated hemolytic anemia in dogs: 151 cases (1993\u20132002)","volume":"226","author":"Weinkle T.K.","year":"2005","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1939-1676.2006.tb02915.x","article-title":"Detection of activated platelets in dogs with primary immune\u2010mediated hemolytic anemia","volume":"20","author":"Weiss D.J.","year":"2006","journal-title":"Journal of Veterinary Internal Medicine"}],"container-title":["Journal of Small Animal Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jsap.70202","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jsap.70202","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jsap.70202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:19:37Z","timestamp":1789622377000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jsap.70202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":39,"alternative-id":["10.1111\/jsap.70202"],"URL":"https:\/\/doi.org\/10.1111\/jsap.70202","archive":["Portico"],"relation":{},"ISSN":["0022-4510","1748-5827"],"issn-type":[{"value":"0022-4510","type":"print"},{"value":"1748-5827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"2026-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jsap.70202"}}